Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Aspira Women's Health215 enrolled

Overview

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

Study Type

OBSERVATIONAL

Enrollment

215

Conditions

Adnexal Mass Germline BRCA1 Gene Mutation Germline BRCA2 Gene Mutation Hereditary Breast and Ovarian Cancer

Interventions

OVA360OTHER

Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key inclusion criteria: * Female subject * 18 years of age or older Cohort A specific inclusion criteria: • Diagnosed with a pelvic mass Cohort B specific inclusion criteria: * Diagnosed with a pelvic mass * Undergoing genetic testing through our commercial offering Cohort C specific inclusion criteria: • Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer. Exclusion Criteria: * n/a

Locations (1)

Silvana Franco

Austin, Texas, United States

Outcomes

Primary Outcomes

OVA360

Identify the molecular key driver of Ovarian cancer and develop a diagnostic test for early Ovarian cancer detection

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.